BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamarca A, Clouston H, Barriuso J, McNamara MG, Frizziero M, Mansoor W, Hubner RA, Manoharan P, O'Dwyer S, Valle JW. Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. J Clin Med 2019;8:E1630. [PMID: 31590343 DOI: 10.3390/jcm8101630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 van der Velden D, Staal F, Aalbersberg E, Castagnoli F, Wilthagen E, Beets-tan R. Prognostic value of CT characteristics in GEP-NET: a systematic review. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103713] [Reference Citation Analysis]
2 Heijkoop B, Perera M, Kelly BD, Bolton D. Metastatic neuroendocrine tumour presenting as a testicular mass. BMJ Case Rep 2021;14:e240042. [PMID: 33541948 DOI: 10.1136/bcr-2020-240042] [Reference Citation Analysis]
3 Mitrovic-jovanovic M, Grubor N, Milosevic S, Jankovic A, Stosic K, Ostojic S, Ninic A, Micev M, Kovac JD. Total Pancreatectomy for Multicentric Cystic Neuroendocrine Tumor of the Pancreas: A Case Report. Diagnostics 2022;12:1003. [DOI: 10.3390/diagnostics12041003] [Reference Citation Analysis]
4 Modlin IM, Kidd M, Frilling A, Falconi M, Filosso PL, Malczewska A, Kitz A. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Ann Surg 2021;274:481-90. [PMID: 34183517 DOI: 10.1097/SLA.0000000000005026] [Reference Citation Analysis]